Skip to content

 

More Information About CAR T-cell Therapy

For Patients and Caregivers


From the University of Chicago Medicine:

Cellular Immunotherapy: CAR T-cell Therapy for Pediatric Cancer

The University of Chicago Medicine is one of the first sites in the U.S. certified to offer CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL).


The Immunotherapy Revolution

Immunotherapies – powerful treatments that activate the body’s own defense mechanisms to attack cancer cells and halt tumor growth are revolutionizing the way we treat cancer. From basic research to patient care, the University of Chicago Medicine is at the forefront of these new and promising treatments.

 

Other trusted resources:

Scientific Journal Articles

Read scientific journal articles about CAR T-cell therapy research.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. 
Grupp SA, Kalos M, Barrett D, et al. New England Journal of Medicine, 368(16), April 18, 2013.

Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels.
Kochenderfer JN, Somerville RPT, Lu T, et al. Journal of Clinical Oncology, 35(16), June 1, 2017.

Chimeric antigen receptor T cells for sustained remissions in leukemia
Maude SL, Frey N, Shaw PA, et al.  New England Journal of Medicine, 371(16), October 16, 2014.

 

 

 

UChicago Medicine Cancer Care Locations

Request an Appointment

* Required Field
Appointment Type *